• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Alexion Pharmaceuticals

Alexion Pharmaceuticals

Alexion Pharmaceuticals Inc ALXN 4 Star

Last Price$176.24Day Change (%)3.15%
Open Price$175.32Day Change ($)5.39
Day Range170.03–176.2952-Week Range150.06–208.88

As of Wed 9/2/2015 5:00:00 PM | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. European Commission Grants Marketing Authorization for Kanuma™ (sebelipase alfa) for the Treatment of Patients of All Ages with Lysosomal Acid Lipase Deficiency (LAL-D)

    European Commission Grants Marketing Authorization for Kanuma™ (sebelipase alfa) for the Treatment of Patients of All Ages with Lysosomal Acid Lipase Deficiency (LAL-D)

  2. European Commission Grants Marketing Authorization for Strensiq™ (asfotase alfa) for the Treatment of Patients with Pediatric-Onset Hypophosphatasia (HPP)

    European Commission Grants Marketing Authorization for Strensiq™ (asfotase alfa) for the Treatment of Patients with Pediatric-Onset Hypophosphatasia (HPP)

  3. UPDATE: Charting the U.S. markets' technical cross currents

    UPDATE: Charting the U.S. markets' technical cross currents

  4. Charting the U.S. markets' technical cross currents

    Charting the U.S. markets' technical cross currents

  5. Blueprint Medicines Reports Second Quarter 2015 Financial Results and Provides Business Update

    Blueprint Medicines Reports Second Quarter 2015 Financial Results and Provides Business Update

  6. Medalist Funds Like These Large-Cap Stocks

    We crunch the numbers to see which stocks are most widely held among analyst-recommended large-cap funds.

  7. Which Funds Own My Stock?

    Ownership data provide a look at who else owns the company.

  8. A Rare Approach Widens the Moat for This Biotech

    Alexion's diversifying pipeline and focus on attractive rare-disease markets are strengthening its competitive position.

  9. Our 5 Nominees for Domestic-Stock Fund Manager of the Year

    Standing out in a good year for stocks.

  10. How to Avoid Unpleasant Surprises

    Buying a country or sector fund isn't as easy as it seems.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.